Last reviewed 2026-05-22 · How we verify

Chlorobenzoxamin (CHLORBENZOXAMINE)

Phase 2 active Small molecule ✓ Verified May 2026

Chlorobenzoxamin (generic name: CHLORBENZOXAMINE) is a chlorbenzoxamine drug. It is currently in Phase 2 development for Gastric ulcer.

Chlorobenzoxamine works by blocking the action of certain chemicals in the body that contribute to the development of gastric ulcers.

Chlorobenzoxamine is a small molecule. It has multiple synonyms, including chlorobenzoxamine, chlorobenzoxamine, and clorbensoxamina.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CHLORBENZOXAMINE
Drug class	chlorbenzoxamine
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your stomach lining is like a delicate garden. Chlorobenzoxamine helps protect the garden by blocking the chemicals that can damage it, reducing inflammation and promoting healing. This helps to prevent stomach ulcers from forming or getting worse.

Approved indications

Gastric ulcer

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Chlorobenzoxamin CI brief — competitive landscape report
Chlorobenzoxamin updates RSS · CI watch RSS

Frequently asked questions about Chlorobenzoxamin

What is Chlorobenzoxamin?

Chlorobenzoxamin (CHLORBENZOXAMINE) is a chlorbenzoxamine drug, indicated for Gastric ulcer.

How does Chlorobenzoxamin work?

Chlorobenzoxamine works by blocking the action of certain chemicals in the body that contribute to the development of gastric ulcers.

What is Chlorobenzoxamin used for?

Chlorobenzoxamin is indicated for Gastric ulcer.

What is the generic name of Chlorobenzoxamin?

CHLORBENZOXAMINE is the generic (nonproprietary) name of Chlorobenzoxamin.

What drug class is Chlorobenzoxamin in?

Chlorobenzoxamin belongs to the chlorbenzoxamine class. See all chlorbenzoxamine drugs at /class/chlorbenzoxamine.

What development phase is Chlorobenzoxamin in?

Chlorobenzoxamin is in Phase 2.

Drug class: All chlorbenzoxamine drugs
Therapeutic area: All drugs in Other
Indication: Drugs for Gastric ulcer

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing